Eric I. Richman, President and Chief Executive Officer

Mr. Richman has extensive experience in the development and commercialization of novel biotechnology-based therapeutics and brings significant leadership, operational and strategic experience. Prior to joining Tyrogenex, Eric served as President & CEO of PharmAthene (NYSE: PIP). Previously, Eric was part of the founding team at MedImmune, where he was responsible for the U.S. launch of MedImmune’s first commercial product CytoGam®, and was an integral part of the global launch teams for marketed products including Synagis®. He began his career at HealthCare Ventures, a Venture Capital firms focused on life sciences.

Eric currently serves on several boards including Therabron, Tyrogenex, PharmAthene, ADMA Biologics and formerly was director of Lev Pharmaceuticals (sold to Viropharma) and American Bank (sold to Congressional Bancshares). Eric is currently a Venture Partner at Brace Pharma Capital.  Eric completed his undergraduate education at the Sophie Davis School of Biomedical Education and earned his MBA from the American Graduate School of International Management.

Michael D. Webb, Director

Michael D. Webb is a Director of Tyrogenex. He has more than 25 years experience in growing biotechnology companies and a track record that includes raising more than $350 million in private and public equity markets. Previously, he was president and CEO of Allegro Diagnostic Corp., a venture-backed, molecular diagnostics company focused on lung cancer that was acquired by Veracyte in 2014. Prior to that, he founded and served as president and CEO for Anchor Therapeutics, Inc. During his time as president and CEO of EPIX Pharmaceuticals, he led the company from “A”-round financing to an industry leadership position in pharmaceuticals for diagnostic imaging and listing on NASDAQ.

Mr. Webb has served as Chairman of the Massachusetts Biotechnology Council, founding chairman of the United Way of Massachusetts Bay’s Math, Science and Technology Initiative and on several boards. Mr. Webb holds an MBA from Northwestern University, a masters in international relations from Sussex University and a B.A./B.S. in biochemistry and economics from the University of Kansas.

Daniel E. Salazar, Ph.D., Acting SVP, Drug Development

Daniel E. Salazar Ph.D. is Brace Pharma Capital’s Vice President of Clinical & Regulatory and is also the Chief Scientific Officer at EMS Pharma. Dan has more than 25 years of experience in drug discovery, development, regulatory submissions and organizational leadership while working at Marion Laboratories, Bristol-Myers Squibb, Daiichi Sankyo and Otsuka. He has made significant contributions to over 40 IND filings and 9 NDAs. Dr. Salazar completed his undergraduate education at Princeton University where he majored in Biology and his Doctor of Pharmaceutical Science from the State University of New York at Buffalo.  He is also an Adjunct Professor in the Department of Pharmaceutical Sciences, University of Florida.